Site-Directed Mutagenesis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase at Amino Acid Position 138
- 1 February 2001
- Vol. 280 (1), 97-106
- https://doi.org/10.1006/viro.2000.0742
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?Reviews in Medical Virology, 1996
- 1,2,3-Triazole-[2,5-Bis-O-(tert-butyldimethylsilyl)-.beta.-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) Analogs: Synthesis and Anti-HIV-1 ActivityJournal of Medicinal Chemistry, 1994
- Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1994
- Sensitivity of (138 Glu → Lys) Mutated Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) to HIV-1-Specific RT InhibitorsBiochemical and Biophysical Research Communications, 1994
- Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.Proceedings of the National Academy of Sciences, 1993
- Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3-N-methyl-thymine]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-Biochemical Pharmacology, 1993
- HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse TranscriptaseVirology, 1993
- 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2', 5'-bis-O-(tert-butyldimethylsilyl)-.beta.-D-xylo- and -ribofuranose]-3'-spiro-5''-[4''-amino-1'', 2''-oxathiole 2'', 2''-dioxide] (TSAO) pyrimidine nucleosidesJournal of Medicinal Chemistry, 1992
- 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.Proceedings of the National Academy of Sciences, 1992
- [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1Antimicrobial Agents and Chemotherapy, 1992